Select Bibliography

Select Bibliography

Filter by any of these (after searching):

Federally Funded Research

There are 738 items

Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance)

Google Scholar

Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80802

A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study.

Google Scholar

Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0426

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426

PubMed

PMC

QxMD

Google Scholar

Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0426

A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer.

Google Scholar

Adjei, A. A. , Molina, J. R. , Hillman, S. L. , Luyun, R. F. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0326

Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Advani, Pooja P. , Ballman, Karla V. , Dockter, Travis J. ... - - J. Clin. Oncol - 2016

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831

Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.

Google Scholar

Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831

Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series

Google Scholar

Al-Daghmin, A , Sokoloff, MH , Halabi, S , Sanford, BL , Eastham, JA ... - AUA - J Urology - 2014

Abstract - Primary Endpoint - Long-Term-Followup Analysis - GU - CALGB-9687

Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver

Google Scholar

Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N014A

NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity

Google Scholar

Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary Endpoint - Preliminary Analysis - GI - NCCTG-N044J

Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147.

Google Scholar

Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0147

Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver.

Google Scholar

Alberts, S. , Mahoney, M. R. , Donohue, J. H. , Roh, M. S. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N9945

Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849

Google Scholar

Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - GI - N0849

Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Alberts, Steven R. , Fitch, Tom R. , Kim, George P. ... - - Am. J. Clin. Oncol. - 2012

Manuscript - Primary Endpoint - Primary Analysis - GI - N044J

Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Alberts, Steven R. , Reid, Joel M. , Morlan, Bruce W. , Farr, Gist H. ... - - Am. J. Clin. Oncol. - 2012

Manuscript - Primary Endpoint - Primary Analysis - GI - N0041

Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66

PubMed

PMC

QxMD

DOI

Google Scholar

Alberts, Steven R. , Roh, Mark S. , Mahoney, Michelle R. ... - - J Clin Oncol - 2010

Manuscript - Primary Endpoint - Primary Analysis - GI - N9945

Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer

PubMed

PMC

QxMD

DOI

Google Scholar

Alberts, Steven R. , Sargent, Daniel J. , Nair, Suresh ... - - JAMA - 2012

Manuscript - Primary Endpoint - Primary Analysis - GI - N0147

Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.

PubMed

DOI

Google Scholar

Alberts, Steven R , Sande, Jonathan R , Foster, Nathan R ... - - J Gastrointest Cancer - 2007

Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-N9943

Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial.

PubMed

Google Scholar

Alberts, Steven R , Suman, Vera J , Pitot, Henry C ... - - J Gastrointest Cancer - 2007

Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-964251

Phase II clinical trial of denileukin diftitox in combination with rituximab in previously untreated follicular B-cell non-Hodgkins lymphoma

Google Scholar

Ansell, S. M. , Tang, H. , Nowakowski, G. S. , Nikcevich, D. A. ... - ASH - 53rd ASH Annual Meeting and Exposition - 2010

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0682

Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma

PubMed

PMC

QxMD

DOI

Google Scholar

Ansell, Stephen M. , Inwards, David J. , Rowland, Kendrith M. ... - - Cancer - 2008

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N0186

Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study

PubMed

PMC

QxMD

DOI

Google Scholar

Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Lancet Oncol - 2011

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N038H

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma

PubMed

PMC

QxMD

DOI

Google Scholar

Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Leukemia - 2012

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0682

Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data

PubMed

PMC

QxMD

Google Scholar

Apoe, Ogheneruona , Jung, Sin-Ho , Liu, Heshan , Seisler, Drew K ... - - Am J Hematol Oncol - 2016

Manuscript - Primary Endpoint - Preliminary Analysis - Prevention - CALGB-70806

Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.

PubMed

DOI

Google Scholar

Ashley, Amanda C , Sargent, Daniel J , Alberts, Steven R ... - - Cancer - 2007

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-9741

Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993).

Google Scholar

Atherton, P. , Burger, K. , Loprinzi, C. , Miller, R. , Jatoi, A. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - NCCTG-N0993

Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993)

PubMed

PMC

QxMD

DOI

Google Scholar

Atherton, Pamela J. , Burger, Kelli N. , Loprinzi, Charles L. ... - - Support Care Cancer - 2012

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N0993

The Complementary Nature of Patient-Reported Outcomes (PROs) and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591)

PubMed

PMC

QxMD

DOI

Google Scholar

Atherton, Pamela J. , Watkins-Bruner, Deborah W. , Gotay, Carolyn ... - - J Pain Symptom Manage - 2015

Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - N0591

Patient Reported Outcomes Questionnaire Compliance in Cancer Cooperative Group Trials (Alliance N0992)

PubMed

PMC

QxMD

DOI

Google Scholar

Atherton, Pamela J , Burger, Kelli N , Pederson, Levi D ... - - Clin Trials - 2016

Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - N0992

Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903

PubMed

PMC

QxMD

DOI

Google Scholar

Atkinson, Thomas M. , Halabi, Susan , Bennett, Antonia V. ... - - Pain Med - 2012

Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-70903

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Google Scholar

Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10502

A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.

Google Scholar

Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

PubMed

PMC

QxMD

DOI

Google Scholar

Attar, Eyal C. , Johnson, Jeffrey L. , Amrein, Philip C. ... - - J. Clin. Oncol. - 2013

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

PubMed

PMC

QxMD

DOI

Google Scholar

Baer, MR , George, SL , Sanford, BL , Mrózek, K , Kolitz, JE ... - - Leukemia - 2011

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-9720

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Baggstrom, Maria Q. , Socinski, Mark A. , Wang, Xiaofei F. , Gu, Lin ... - - J Thorac Oncol - 2017

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30607 , CALGB-70701

Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).

PubMed

DOI

Google Scholar

Bajorin, Dean F , Halabi, Susan ... - - Clin Genitourin Cancer - 2009

Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-99903

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

PubMed

PMC

QxMD

DOI

Google Scholar

Ballman, Karla V. , Buckner, Jan C. , Brown, Paul D. ... - - Neuro-oncol - 2007

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N047D

Age and the Risk of Paclitaxel‐Induced Neuropathy in Women with Early‐Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101

PubMed

PMC

QxMD

DOI

Google Scholar

Barginear, Myra , Dueck, Amylou C. , Allred, Jacob B. ... - - Oncologist - 2019

Manuscript - Primary Endpoint - Primary Analysis - Older Adult - A151411 , CALGB-40101 , CALGB-70301

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

PubMed

DOI

Google Scholar

Bartlett, N L , Niedzwiecki, D , Johnson, J L , Friedberg, J W ... - - Ann. Oncol. - 2007

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59804

A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804

Google Scholar

Bartlett, N. , Niedzwiecki, D. , Johnson, J. , Friedberg, J. W. ... - - Proc Am Soc Clin Oncol - 2003

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59804

Phase II Study of 9-aminocamptothecin in Previously Treated Lymphomas: Results of Cancer and Leukemia Group B 9551

PubMed

PMC

QxMD

DOI

Google Scholar

Bartlett, Nancy L. , Johnson, Jeffrey L. , Wagner-Johnston, Nina ... - - Cancer Chemother. Pharmacol. - 2009

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-9551

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

PubMed

DOI

Google Scholar

Bartlett, Nancy L , Wilson, Wyndham H , Jung, Sin-Ho , Hsi, Eric D ... - - J. Clin. Oncol. - 2019

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50303

The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)

PubMed

PMC

QxMD

Google Scholar

Barton, D. L. , Atherton, P. J. , Bauer, B. A. , Moore, D. F. Jr ... - - J Support Oncol - 2011

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N01C5

Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9

PubMed

PMC

QxMD

Google Scholar

Barton, D. L. , Lavasseur, B. I. , Sloan, J. A. , Stawis, A. N. ... - - J. Clin. Oncol. - 2010

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N05C9

A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9

Google Scholar

Barton, D. L. , Lavasseur, B. , Sloan, J. A. , Stella, P. J. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N05C9

Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2

Google Scholar

Barton, D. L. , Liu, H. , Dakhil, S. R. , Linquist, B. M. ... - - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N07C2

Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2

PubMed

PMC

QxMD

Google Scholar

Barton, D. L. , Liu, H. , Dakhil, S. R. , Linquist, B. , Sloan, J. A. ... - - J. Natl. Cancer Inst. - 2013

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N07C2

Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7

Google Scholar

Barton, D. L. , Moraska, A. R. , Sood, A. , Sloan, J. A. , Suh, J. J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N05C7

Can gabapentin improve control of delayed nausea and vomiting (N/V)? A phase III placebo controlled trial, N08C3 (Alliance)

Google Scholar

Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - Support Care Cancer - 2013

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3

Does gabapentin prevent delayed chemotherapy-induced nausea and vomiting (N/V)? Results of a randomized placebo controlled trial, NCCTG N08C3 (Alliance)

Google Scholar

Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3

A pilot, multi-dose, placebo-controlled evaluation of american ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA

Google Scholar

Barton, D. L. , Soori, G. S. , Bauer, B. , Sloan, J. , Johnson, P. A. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N03CA

A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA

PubMed

PMC

QxMD

Google Scholar

Barton, D. L. , Wos, E. J. , Qin, R. , Mattar, B. I. , Green, N. B. ... - - Support Care Cancer - 2011

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N06CA

A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA

Google Scholar

Barton, D. L. , Wos, E. , Qin, R. , Mattar, B. , Green, N. , Lanier, K. ... - - J. Clin. Oncol. - 2009

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N06CA

The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9

PubMed

PMC

QxMD

DOI

Google Scholar

Barton, Debra L. , Burger, Kelli , Novotny, Paul J. , Fitch, Tom R. ... - - Support Care Cancer - 2013

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N00C9

Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T. , Gill, Paula ... - - Support Care Cancer - 2018

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N10C1

Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance)

Google Scholar

Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T , Gill, Paula ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N10C1

Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA

PubMed

PMC

QxMD

DOI

Google Scholar

Barton, Debra L. , Soori, Gamini S. , Bauer, Brent A. ... - - Support Care Cancer - 2010

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N03CA

Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy, NCCTG N08C3 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Barton, Debra L. , Thanarajasingam, Gita , Sloan, Jeff A. ... - - Cancer - 2014

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3

Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3.

PubMed

DOI

Google Scholar

Barton, Debra L , Wender, Donald B , Sloan, Jeff A , Dalton, Robert J ... - - J. Natl. Cancer Inst. - 2007

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - NCCTG-N02C3

Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-Institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002)

PubMed

PMC

QxMD

DOI

Google Scholar

Bashey, Asad , Owzar, Kouros , Johnson, Jeffrey L. ... - - Biol. Blood Marrow Transplant. - 2011

Manuscript - Primary Endpoint - Primary Analysis - Transplant - CALGB-100002

Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y ) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study

Google Scholar

Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2009

Abstract - Primary Endpoint - Primary Analysis - Correl Sci NOS - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

Evaluation of mode equivalence of the MSKCC Bowel Function Instrument, LASA Quality of Life, and Subjective Significance Questionnaire items administered by Web, interactive voice response system (IVRS), and paper

PubMed

PMC

QxMD

DOI

Google Scholar

Bennett, Antonia V. , Keenoy, Kathleen , Shouery, Marwan ... - - Qual Life Res - 2016

Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - NCT01458509

Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).

Google Scholar

Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Primary Analysis - GI - A021202

High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials

Google Scholar

Berry, D. A. , Ueno, N. T. , Johnson, M. M. , Lei, X. , Lopez, V. ... - - Breast Cancer Res. Treat. - 2007

Abstract - Primary Endpoint - Primary Analysis - Breast - INT-0163

An intensive sequenced adjuvant chemotherapy regimen for breast cancer.

PubMed

Google Scholar

Bhardwaj, S , Holland, J F ... - - Cancer Invest. - 1993

Manuscript - Primary Endpoint - Primary Analysis - Breast - C8743

Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105

Google Scholar

Blackstock, A. W. , Socinski, M. A. , Bogart, J. , Gu, L. , Wang, X. ... - - J. Clin. Oncol. - 2006

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30105

Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma

Google Scholar

Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - A071101

Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

Google Scholar

Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502

Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism

PubMed

PMC

QxMD

DOI

Google Scholar

Blum, K. A. , Jung, S.-H. , Johnson, J. L. , Lin, T. S. , Hsi, E. D. ... - - Ann Oncol - 2010

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502

Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance)

Google Scholar

Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50904

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

PubMed

DOI

Google Scholar

Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Leuk. Lymphoma - 2007

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50206

Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.

PubMed

DOI

Google Scholar

Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Cancer - 2006

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Lymphoma - CALGB-9153

Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).

PubMed

DOI

Google Scholar

Blum, Kristie A , Polley, Mei-Yin , Jung, Sin-Ho , Dockter, Travis J ... - - Cancer - 2019

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50904

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

Google Scholar

Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012

Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503)

PubMed

PMC

QxMD

DOI

Google Scholar

Blum, William , Sanford, Ben L. , Klisovic, Rebecca ... - - Leukemia - 2017

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503

Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study.

Google Scholar

Bogart, J. , Watson, D. , Seagren, S. , Blackstock, W. , Wang, X. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39904

Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904

PubMed

PMC

QxMD

DOI

Google Scholar

Bogart, Jeffrey A. , Hodgson, Lydia , Seagren, Stephen L. ... - - J Clin Oncol - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39904

Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52

PubMed

PMC

QxMD

Google Scholar

Bolton, J. S. , O'Connell, M. J. , Mahoney, M. R. , Farr, G. H. Jr ... - - Clin Colorectal Cancer - 2012

Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-924652

Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance)

Google Scholar

Borad, Mitesh J. , Foster, Nathan R. , Martin, Peter R. ... - ESMO GI - Ann. Oncol. - 2016

Abstract - Primary Endpoint - Preliminary Analysis - Experimental - N1153

The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial

Google Scholar

Boughey, J. , Suman, V. , Mittendorf, E. , Ahrendt, G. , Wilke, L. ... - - Cancer Res. - 2012

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 Clinical Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Boughey, Judy C. , Suman, Vera J. , Mittendorf, Elizabeth A. ... - - JAMA - 2013

Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM)

Google Scholar

Brown, P. D. , Krishnan, S. , Sarkaria, J. , Wu, W. , Mischel, P. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0177

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Brown, Paul D. , Anderson, S. Keith , Carrero, Xiomara W. ... - - Neurooncol Pract - 2015

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - NCCTG-86-72-51

NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases.

Google Scholar

Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - SNO - Neuro Oncol - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574

NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases

Google Scholar

Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574

N107C/CEC.3 (Alliance/NCIC): Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease

Google Scholar

Brown, Paul D. , Ballman, Karla V. , Cerhan, Jane H. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2016

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N107C

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases

PubMed

PMC

QxMD

DOI

Google Scholar

Brown, Paul D. , Jaeckle, Kurt , Ballman, Karla V. , Farace, Elana ... - - JAMA - 2016

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

PubMed

PMC

QxMD

DOI

Google Scholar

Brown, Paul D. , Krishnan, Sunil , Sarkaria, Jann N. , Wu, Wenting ... - - J Clin Oncol - 2008

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0177

Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial

PubMed

PMC

QxMD

DOI

Google Scholar

Brown, Paul D , Ballman, Karla V , Cerhan, Jane H , Anderson, S Keith ... - - Lancet Oncol. - 2017

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N107C

Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer

PubMed

PMC

QxMD

DOI

Google Scholar

Bryce, Alan H. , Mattar, Bassam , Hillman, Shauna L. , Adjei, Alex A. ... - - Am. J. Clin. Oncol. - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-0027

Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade.

PubMed

DOI

Google Scholar

Buckner, Jan C , O'Fallon, Judith R , Dinapoli, Robert P ... - - J. Neurooncol. - 2007

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-94-72-52

Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study

Google Scholar

Burstein, H. J. , Barry, W. T. , Cirrincione, C. , Chew, H. K. ... - - Cancer Res. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40302

Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Burstein, Harold J. , Cirrincione, Constance T. , Barry, William T. ... - - J. Clin. Oncol - 2014

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40302

ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer

Google Scholar

Buzdar, A. , Suman, V. , Meric-Bernstam, F. , Leitch, M. , Ellis, M. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

PubMed

PMC

QxMD

DOI

Google Scholar

Buzdar, Aman U , Suman, Vera J , Meric-Bernstam, Funda ... - - Lancet Oncol. - 2013

Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Byrd, John C. , Ruppert, Amy S. , Heerema, Nyla A. ... - - Blood Adv - 2018

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10404

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

PubMed

Google Scholar

Byrd, John C , Peterson, Bercedis L , Rai, Kanti R , Hurd, David ... - - Leuk. Lymphoma - 2009

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19901

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

PubMed

PMC

QxMD

DOI

Google Scholar

Carey, Lisa A. , Berry, Donald A. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2016

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40601

Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer

Google Scholar

Carey, Lisa A. , Berry, Donald A. , Ollila, David , Harris, Lyndsay ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - C40601

Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392)

Google Scholar

Chauhan, C. , Atherton, P. J. , Satele, D. , Dueck, A. C. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Health Outcome - NCCTG-N0392

Phase 2 Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive-Stage Small Cell Lung Cancer, N0423

PubMed

PMC

QxMD

DOI

Google Scholar

Chee, Cheng E. , Jett, James R. , Bernath, Albert M. ... - - Cancer - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0423

Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB)

PubMed

PMC

QxMD

DOI

Google Scholar

Cheville, Andrea L. , Sloan, Jeff A. , Northfelt, Donald W. ... - - Support Care Cancer - 2009

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N01CB

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - - J. Clin. Oncol - 2017

Manuscript - Primary Endpoint - Primary Analysis - GU - A031203

CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial.

Google Scholar

Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016

Abstract - Primary Endpoint - Primary Analysis - GU - A031203

Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

Google Scholar

Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017

Abstract - Primary Endpoint - Primary Analysis - GU - A031203

Sentinel Lymph Node Biopsy Accurately Stages the Regional Lymph Nodes for T1-T2 Oral Squamous Cell Carcinomas: Results of a Prospective Multi-Institutional Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Civantos, Francisco J. , Zitsch, Robert P. , Schuller, David E. ... - - J Clin Oncol - 2010

Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z0360

Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803)

PubMed

PMC

QxMD

DOI

Google Scholar

Cohen, Harvey Jay , Lan, Lan , Archer, Laura ... - - J Geriatr Oncol - 2012

Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - C70103 , CALGB-70803

Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

PubMed

DOI

Google Scholar

Cornett, Wendy R , McCall, Linda M , Petersen, Rebecca P ... - - J. Clin. Oncol. - 2006

Manuscript - Primary Endpoint - Primary Analysis - Experimental - Z0020

ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer

Google Scholar

Cote, R. , Giuliano, A. E. , Hawes, D. , Ballman, K. V. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010

Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention.

PubMed

DOI

Google Scholar

Croghan, Ivana T , Hurt, Richard D , Dakhil, Shaker R ... - - Mayo Clin. Proc. - 2007

Manuscript - Primary Endpoint - Primary Analysis - Prevention - NCCTG-N99C4

N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy

PubMed

PMC

QxMD

DOI

Google Scholar

Crozier, Jennifer A. , Advani, Pooja P. , LaPlant, Betsy ... - - Clin. Breast Cancer - 2016

Manuscript - Primary Endpoint - Primary Analysis - Breast - N0436

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

PubMed

PMC

QxMD

DOI

Google Scholar

Czuczman, M S , Leonard, J P , Jung, S , Johnson, J L , Hsi, E D ... - - Ann. Oncol. - 2012

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50402

A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402

Google Scholar

Czuczman, M. S. , Johnson, J. L. , Jung, S. ... - - Ann. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50402

Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.

PubMed

DOI

Google Scholar

Czuczman, Myron S , Porcu, Pierluigi , Johnson, Jeffrey ... - - Leuk. Lymphoma - 2007

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59901

p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study

Google Scholar

D'Amico, A. V. , Halabi, S. , Vollmer, R. , Loffredo, M. , Mcmahon, E. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2007

Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-159807 , CALGB-9682

p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).

PubMed

DOI

Google Scholar

D'Amico, Anthony V , Halabi, Susan , Vollmer, Robin ... - - Urology - 2008

Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-159807 , CALGB-9682

Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS).

Google Scholar

D'Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091103

The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: Final analysis of CALGB 9761

Google Scholar

D'Cunha, J. , Wang, X. , Groth, S. S. , Vollmer, R. T. ... - IASLC (WCLC) - J Thorac Oncol - 2009

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9761

Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909

PubMed

PMC

QxMD

DOI

Google Scholar

Damon, Lloyd E. , Johnson, Jeffrey L. , Niedzwiecki, Donna ... - - J Clin Oncol - 2009

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59909

Randomized Trial of Mediastinal Lymph Node Sampling versus Complete Lymphadenectomy During Pulmonary Resection in Patients with N0 or N1 (Less than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial

Google Scholar

Darling, G. , Allen, M. , Decker, P. , Ballman, K. , Landreneau, R. ... - AATS - American Association for Thoracic Oncology 90th Annual Meeting, Toronto, ON, Canada - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient with N0 or N1 (Less Than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Darling, Gail E. , Allen, Mark S. , Decker, Paul A. , Ballman, Karla ... - - J. Thorac. Cardiovasc. Surg. - 2011

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030

A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.

PubMed

DOI

Google Scholar

Dawson, Nancy A , Halabi, Susan , Ou, San-San , Biggs, David D ... - - Clin Genitourin Cancer - 2008

Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-90004

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

PubMed

PMC

QxMD

DOI

Google Scholar

DeAngelo, Daniel J. , Yu, Daohai , Johnson, Jeffrey L. ... - - Blood - 2007

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19801

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial

PubMed

PMC

QxMD

DOI

Google Scholar

DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Ann. Surg. - 2013

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - ACOSOG-Z9000

Placebo-Controlled Randomized Trial of Adjuvant Imatinib Mesylate Following the Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST)

PubMed

PMC

QxMD

DOI

Google Scholar

DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Lancet - 2009

Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001

Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000

Google Scholar

Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008

Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9000

Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001

Google Scholar

Dematteo, R. , Owzar, K. , Maki, R. , Pisters, P. , Blackstein, M. ... - ASCO - ASCO Annual Meeting - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001

In-dwelling catheters are superior to talc pleurodesis in the management of malignant pleural effusions

Google Scholar

Demmy, T. L. , Gu, L. , Burkhalter, J. , Toloza, E. M. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30102

Optimal Management of Malignant Pleural Effusions (Results of CALGB 30102)

PubMed

PMC

QxMD

Google Scholar

Demmy, Todd L. , Gu, Lin , Burkhalter, Jack E. , Toloza, Eric M. ... - - J Natl Compr Canc Netw - 2012

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30102

Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance).

PubMed

DOI

Google Scholar

Deshields, Teresa L , Dueck, Amylou C , Rogers, Kerry ... - - Leuk. Lymphoma - 2019

Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-10501 , CALGB-70603

A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502

Google Scholar

Devine, S. M. , Owzar, K. , Blum, W. , Deangelo, D. , Stone, R. M. ... - ASH - ASH Annual Meeting Abstracts - 2012

Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100103

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502

PubMed

PMC

QxMD

DOI

Google Scholar

Devine, Steven M. , Owzar, Kouros , Blum, William , Mulkey, Flora ... - - J. Clin. Oncol - 2015

Manuscript - Primary Endpoint - Primary Analysis - Transplant - CALGB-100103

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Dickler, Maura N. , Barry, William T. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2016

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40503

Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive Advanced Breast Cancer: CALGB 40503 (Alliance)

Google Scholar

Dickler, Maura N. , Barry, William Thomas ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40503

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma†

PubMed

PMC

QxMD

DOI

Google Scholar

Dickson, M. A. , Mahoney, M. R. , Tap, W. D. , D'Angelo, S. P. ... - - Ann. Oncol - 2016

Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091102

Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma

Google Scholar

Dickson, Mark Andrew , Mahoney, Michelle R. , Marchello, Benjamin T. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091102

Features Associated with Successful Recruitment of Diverse Patients onto Cancer Clinical Trials: Report from the American College of Surgeons Oncology Group

PubMed

PMC

QxMD

DOI

Google Scholar

Diehl, Kathleen M. , Green, Erin M. , Weinberg, Armin ... - - Ann. Surg. Oncol. - 2011

Manuscript - Primary Endpoint - Primary Analysis - Disparities - Comprehensive

Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production

Google Scholar

Ding, W. , Shanafelt, T. D. , Lesnick, C. , Sassoon, T. , Secreto, C. ... - ASH - Blood - 2012

Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - N1087

Akt Inhibitor MK2206 Selectively Targets CLL B-cell Receptor Induced Cytokines, Mobilizes Lymphocytes and Synergizes with Bendamustine to Induce CLL Apoptosis

PubMed

PMC

QxMD

DOI

Google Scholar

Ding, Wei , Shanafelt, Tait D. , Lesnick, Connie E. ... - - Br. J. Haematol. - 2014

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - N1087

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)

Google Scholar

Ding, Wei , Shanafelt, Tait D. , Zent, Clive S. , Leis, Jose F. ... - - Blood - 2013

Abstract - Primary Endpoint - Primary Analysis - Leukemia - N1087

Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion

PubMed

PMC

QxMD

DOI

Google Scholar

Dresler, Carolyn M. , Olak, Jemi , Herndon, James E. ... - - Chest - 2005

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9334

N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM)

Google Scholar

Dronca, R. , Perez, D. , Allred, J. , Maples, W. , Creagan, E. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N0675

Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma

PubMed

PMC

QxMD

DOI

Google Scholar

Dronca, Roxana S. , Allred, Jacob B. , Perez, Domingo G. ... - - Am. J. Clin. Oncol. - 2014

Manuscript - Primary Endpoint - Primary Analysis - Experimental - N0675

CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells

PubMed

PMC

QxMD

DOI

Google Scholar

Du, Juan , Lopez-Verges, Sandra , Pitcher, Brandelyn N. ... - - Cancer Immunol Res - 2014

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-150905 , CALGB-50402 , CALGB-50701

A phase II study of sorafenib in malignant mesothelioma: results of CALGB 30307

PubMed

PMC

QxMD

DOI

Google Scholar

Dubey, Sarita , Jänne, Pasi A. , Krug, Lee , Pang, Herbert ... - - J Thorac Oncol - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30307

CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM)

Google Scholar

Dudek, A. Z. , Kindler, H. L. , Otterson, G. A. , Pang, H. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30601

Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report

PubMed

PMC

QxMD

Google Scholar

Dudek, A. Z. , Pang, H. , Kratzke, R. A. , Otterson, G. A. ... - - J Thorac Oncol - 2012

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30601

Randomized phase 2 study of maintenance pemetrexed versus observation for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB/Alliance) 30901

DOI

Google Scholar

Dudek, Arkadiusz Z. , Wang, Xiaofei , Gu, Lin , Stinchcombe, Thomas ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30901

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

PubMed

DOI

Google Scholar

Duggan, David B , Petroni, Gina R , Johnson, Jeffrey L ... - - J. Clin. Oncol. - 2003

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - C8952

Radiofrequency ablation of stage Ia NSCLC in medically inoperable patients: Results from ACOSOG Z4033 (Alliance) an NCI funded multicenter trial

DOI

Google Scholar

Dupuy, D. E. , Fernando, H. , Hillman, S. , Ng, T. , Tan, A. D. ... - CHEST - Chest - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033

Radiofrequency Ablation of Stage IA NSCLC in Medically Inoperable Patients: Results from the ACOSOG Z4033 (Alliance) Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Dupuy, Damian E. , Fernando, Hiran C. , Hillman, Shauna , Ng, Thomas ... - - Cancer - 2015

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033

A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

Google Scholar

Dy, G. K. , Mandrekar, S. J. , Nelson, G. D. , Ross, H. J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0528

N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2)

Google Scholar

Dy, G. K. , Molina, J. , Qi, Y. , Ansari, R. H. , Thomas, S. ... - - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821

A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261

PubMed

PMC

QxMD

DOI

Google Scholar

Dy, Grace K. , Hillman, Shauna L. , Rowland, Kendrith M. ... - - Cancer - 2010

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0326

Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144

PubMed

PMC

QxMD

Google Scholar

Dy, Grace K. , Hobday, Timothy J. , Nelson, Garth ... - - Clin Colorectal Cancer - 2009

Manuscript - Primary Endpoint - Primary Analysis - GI - N0144

A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without Cediranib as First-Line Therapy in Advanced Non-Small Cell Lung Cancer: North Central Cancer Treatment Group Study N0528

PubMed

PMC

QxMD

DOI

Google Scholar

Dy, Grace K. , Mandrekar, Sumithra J. , Nelson, Garth D. ... - - J Thorac Oncol - 2013

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0528

NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status

PubMed

PMC

QxMD

DOI

Google Scholar

Dy, Grace K. , Molina, Julian R. , Qi, Yingwei , Ansari, Rafat ... - - J Thorac Oncol - 2014

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821

Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma

PubMed

PMC

QxMD

DOI

Google Scholar

D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - Cancer Chemother. Pharmacol. - 2015

Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091103

A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401)

PubMed

PMC

QxMD

DOI

Google Scholar

D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - Lancet Oncol. - 2018

Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091401

A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)

Google Scholar

D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091401

CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer

DOI

Google Scholar

Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-90203

CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer.

DOI

Google Scholar

Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - AUA - Journal of Urology - 2019

Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-90203

Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203

Google Scholar

Edelman, M. J. , Watson, D. M. , Wang, X. , Kratzke, R. A. ... - - J. Clin. Oncol. - 2006

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30203

Final Results of a phase III trial of celecoxib (C) in addition to standard chemotherapy for advanced NSCLC with COX- 2 overexpression: CALGB 30801 (Alliance)

Google Scholar

Edelman, Martin J. , Wang, Xiaofei , Hodgson, Lydia ... - MSTO - Int. J. Radiat. Oncol. Biol. Phys. - 2017

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30801

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Edelman, Martin J. , Wang, Xiaofei , Hodgson, Lydia ... - - J. Clin. Oncol - 2017

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30801

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

PubMed

DOI

Google Scholar

Edelman, Martin J , Watson, Dee , Wang, Xiaofei , Morrison, Carl ... - - J. Clin. Oncol. - 2008

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30203

Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16)

Google Scholar

Edwards, C. G. , Maharry, K. , Mrozek, K. , Schwind, S. , Paschka, P. ... - - Blood - 2011

Abstract - Primary Endpoint - Comprehensive Analysis - Leuk Corr Sci - CALGB-10503 , CALGB-19808 , CALGB-9621

ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer

Google Scholar

Ellis, M. J. , Buzdar, A. U. , Unzeitig, G. W. , Esserman, L. J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031

Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%

Google Scholar

Ellis, M. J. , Suman, V , McCall, L. , Luo, R. , Hoog, J. , Brink, A. ... - AACR - Cancer Res. - 2012

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

PubMed

PMC

QxMD

DOI

Google Scholar

Ellis, Matthew J. , Suman, Vera J. , Hoog, Jeremy , Lin, Li ... - - J. Clin. Oncol. - 2011

Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031

CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer

Google Scholar

Enzinger, P. C. , Burtness, B. , Hollis, D. R. , Niedzwiecki, D. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80403

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers

PubMed

PMC

QxMD

DOI

Google Scholar

Enzinger, Peter C. , Burtness, Barbara Ann , Niedzwiecki, Donna ... - - J. Clin. Oncol - 2016

Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80403 , ECOG-1206

A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study

Google Scholar

Farag, S. , Owzar, K. , Hars, V. , Lazarus, H. M. , Stadtmauer, E. A. ... - ASH - Blood - 2009

Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100101

The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea: Preliminary Results from ACOSOG Z4032 Trial

Google Scholar

Fernando, H. C. , Landreneau, R. , Mandraker, S. , Hillman, S. ... - AATS - American Association of Thoracic Surgery 90th Annual Meeting - 2010

Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - ACOSOG-Z4032

Impact of brachytherapy on local recurrence after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer (NSCLC)

Google Scholar

Fernando, H. , Landreneau, R. , Mandrekar, S. , Nichols, F. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non–Small-Cell Lung Cancer

PubMed

PMC

QxMD

DOI

Google Scholar

Fernando, Hiran C. , Landreneau, Rodney J. , Mandrekar, Sumithra J. ... - - J. Clin. Oncol - 2014

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032

Factors contributing to cancer screening in African Americans

Google Scholar

Ferrans, C. E. , Ryan, C. , Archer, L. E. , Freels, S. , Lan, L. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-119901

Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

DOI

Google Scholar

Fleming, Gini F , Francis, Prudence A , Láng, István ... - SABCS - Ann. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)

Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer

Google Scholar

Fleshman, J. , Sargent, D. , Green, E. , Anvari, M. , Stryker, S. ... - - EJC Supplement - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - INT-0146

Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes

PubMed

PMC

QxMD

DOI

Google Scholar

Fleshman, James , Branda, Megan , Sargent, Daniel J. ... - - JAMA - 2015

Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z6051

Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial.

PubMed

DOI

Google Scholar

Fleshman, James , Sargent, Daniel J , Green, Erin , Anvari, Mehran ... - - Ann. Surg. - 2007

Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-1515

Comparative nocebo findings in older patients enrolled in cancer therapeutic trials: observations from a 446-patient cohort (Alliance A151602)

Google Scholar

Foster, Jared C. , Le-Rademacher, Jennifer G. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Older Adult - A151602 , ACOSOG-Z9001 , NCCTG-97-24-51

Comparative “Nocebo Effects” in Older Patients Enrolled in Cancer Therapeutic Trials: Observations From a 446-Patient Cohort

PubMed

PMC

QxMD

DOI

Google Scholar

Foster, Jared C. , Le-Rademacher, Jennifer G. ... - - Cancer - 2017

Manuscript - Primary Endpoint - Primary Analysis - Older Adult - ACOSOG-Z9001 , A151602 , NCCTG-97-24-51

Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

Google Scholar

Foster, N. R. , Qi, Y. , Shi, Q. , Krook, J. E. , Kugler, J. W. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0424

Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials

PubMed

PMC

QxMD

DOI

Google Scholar

Foster, Nathan R. , Qi, Yingwei , Shi, Qian , Krook, James E. ... - - Cancer - 2011

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0424

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

PubMed

PMC

QxMD

DOI

Google Scholar

Francis, Prudence A. , Regan, Meredith M. , Fleming, Gini F. ... - - N. Engl. J. Med. - 2015

Manuscript - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)

Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602)

PubMed

PMC

QxMD

DOI

Google Scholar

Freedman, Rachel A. , Dockter, Travis J. , Lafky, Jacqueline M. ... - - Oncologist - 2018

Manuscript - Primary Endpoint - Primary Analysis - Older Adult - A171602

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527

PubMed

PMC

QxMD

DOI

Google Scholar

Freedman, Rachel A. , Foster, Jared C. , Seisler, Drew K. ... - - J. Clin. Oncol - 2017

Manuscript - Primary Endpoint - Comprehensive Analysis - Older Adult - A151527 , ACOSOG-Z1031 , ACOSOG-Z1041 , C8541 , C9344 , C9741 , CALGB-40101 , CALGB-40302 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-40603 , CALGB-49907 , CALGB-9342 , CALGB-9840 , N89-30-52 , N9831

Accrual of Older Breast Cancer Patients to Alliance Systemic Therapy Protocols over Time: Alliance A151527 (Multiple)

Google Scholar

Freedman, Rachel A , Seisler, Drew K. , Foster, Jared C. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Primary Endpoint - Comprehensive Analysis - Older Adult - A151527 , ACOSOG-Z1031 , ACOSOG-Z1041 , C8541 , C9344 , C9741 , CALGB-40101 , CALGB-40302 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-40603 , CALGB-49907 , CALGB-9342 , CALGB-9840 , N89-30-52 , N9831

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Google Scholar

Friday, B. B. , Buckner, J. , Anderson, S. K. , Giannini, C. ... - SNO - 15th Annual Meeting of the Society for Neuro-Oncology (SNO) - 2010

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0779

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

PubMed

PMC

QxMD

DOI

Google Scholar

Friday, Bret B. , Anderson, S. Keith , Buckner, Jan , Yu, Chunrong ... - - Neuro Oncol - 2012

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0779

Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101

Google Scholar

Fuchs, C. S. , Tepper, J. E. , Niedzwiecki, D. , Hollis, D. R. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80101

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Fuchs, Charles S. , Niedzwiecki, Donna , Mamon, Harvey J. ... - - J. Clin. Oncol - 2017

Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80101

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254

PubMed

PMC

QxMD

DOI

Google Scholar

Furman, Richard R. , Grossbard, Michael L. , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2011

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-9254

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

PubMed

PMC

QxMD

Google Scholar

Gajewski, T. F. , Salama, A. K. , Niedzwiecki, D. , Johnson, J. ... - - J Transl Med - 2012

Manuscript - Primary Endpoint - Primary Analysis - Experimental - CALGB-500104

NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (RGBM).

Google Scholar

Galanis, E. , Anderson, S. K. , Lafky, J. M. , Kaufmann, T. J. ... - - Neuro-oncology - 2011

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0776

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

PubMed

PMC

QxMD

Google Scholar

Galanis, E. , Anderson, S. K. , Lafky, J. M. , Uhm, J. , Giannini, C. ... - - Clin. Cancer Res. - 2013

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0776

N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)

Google Scholar

Galanis, E. , Jaeckle, K. A. , Maurer, M. J. , Reid, J. M. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N047B

NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

Google Scholar

Galanis, E. , Jaeckle, K. , Anderson, S. , Kaufmann, T. , Uhm, J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0776

Vorinostat in glioblastoma multiforme (Gbm): updated results from phase I and II trials provide the rationale for further clinical development.

Google Scholar

Galanis, E. , Jaeckle, K. , Buckner, J. , Maurer, M. , Hardwick, J. ... - - Ann. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N047B

Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial

Google Scholar

Galanis, E. , Sarkaria, J. , Anderson, K. , Wu, W. , Jaeckle, K. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

PubMed

PMC

QxMD

DOI

Google Scholar

Galanis, Evanthia , Anderson, S Keith , Miller, C Ryan ... - - Neuro-oncology - 2018

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - ABTC-0902 , N0874

A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.

PubMed

DOI

Google Scholar

Galanis, Evanthia , Anderson, S Keith , Twohy, Erin L ... - - Cancer - 2019

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0872

NCCTG N0872 (Alliance): A Randomized Placebo-Controlled Phase II Trial of Bevacizumab Plus Dasatinib in Patients with Recurrent Glioblastoma (GBM)

Google Scholar

Galanis, Evanthia , Anderson, S. Keith , Anastasiadis, Panagiotis Z. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0872

NCCTG N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Alliance)

Google Scholar

Galanis, Evanthia , Anderson, S. Keith , Butowski, Nicholas ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N1174

Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902)

Google Scholar

Galanis, Evanthia , Anderson, S. Keith , Miller, C. Ryan ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

PubMed

PMC

QxMD

DOI

Google Scholar

Galanis, Evanthia , Jaeckle, Kurt A. , Maurer, Matthew J. ... - - J Clin Oncol - 2009

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N047B

Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer

PubMed

PMC

QxMD

DOI

Google Scholar

Garber, Judy E. , Halabi, Susan , Tolaney, Sara M. , Kaplan, Ellen ... - - J Natl Cancer Inst - 2010

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9872

Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.

PubMed

DOI

Google Scholar

Garces, Yolanda I , Okuno, Scott H , Schild, Steven E ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2007

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N9923

A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Garcia-Aguilar, Julio , Shi, Qian , Thomas, Charles R. , Chan, Emily ... - - Ann. Surg. Oncol. - 2012

Manuscript - Primary Endpoint - Preliminary Analysis - GI - ACOSOG-Z6041

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 9480.

PubMed

DOI

Google Scholar

George, Daniel J , Halabi, Susan , Shepard, Timothy F , Sanford, Ben ... - - Clin. Cancer Res. - 2005

Manuscript - Primary Endpoint - Primary Analysis - GU - INT-0159

ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1 - 2 N0 M0 breast Cancer who have a positive sentinel node

Google Scholar

Giuliano, A. E. , Mccall, L. , Beitsch, P. , Whitworth, P. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

Association of occult metastases in sentinel lymph nodes and bone marrow with survival of women with early-stage invasive breast cancer

PubMed

PMC

QxMD

DOI

Google Scholar

Giuliano, Armando E. , Hawes, Debra , Ballman, Karla V. ... - - JAMA - 2011

Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010

Sentinel Lymph Node Dissection With and Without Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Giuliano, Armando E. , Hunt, Kelly K. , Ballman, Karla. V. ... - - JAMA - 2011

Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-term follow-up from the American College of Surgeons Oncology Group (Alliance) Z0011 Randomized Trial

Google Scholar

Giuliano, Armando E , McCall, Linda , Beitsch, Peter ... - ASA - - 2016

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011

Use of gene expression profiling to identify responsive patients treated with carboplatin (Carb), paclitaxel (Pac), and everolimus as first-line treatment for cancer of unknown primary (CUP): NCCTG N0871 (Alliance)

Google Scholar

Goetz, M. , Foster, N. , Meyers, J. , Steen, P. , Visscher, D. ... - - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N0871

Adjuvant mFOLFOX6 +/- Cetuximab in Patients With KRAS Mutant Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147.

Google Scholar

Goldberg, R. , Sargent, D. , Thibodeau, S. , Mahoney, M. , Shields, A. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - GI - N0147

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

PubMed

DOI

Google Scholar

Goldberg, Richard M , Sargent, Daniel J , Morton, Roscoe F ... - - J. Clin. Oncol. - 2004

Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-N9741

Initial results of CALGB 80803: A randomized phase II trial of pet scan-directed combined modality therapy for esophageal cancer (Alliance)

Google Scholar

Goodman, Karyn A. , Niedzwiecki, Donna , Hall, Nathan ... - ASCO GI - J Clin Oncol - 2017

Abstract - Primary Endpoint - Preliminary Analysis - GI - CALGB-80803

Sorafenib for Advanced and Refractory Desmoid Tumors

PubMed

PMC

QxMD

DOI

Google Scholar

Gounder, Mrinal M. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - N. Engl. J. Med. - 2018

Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091105

Phase III, randomized, double blind, placebo (P)-controlled trial of sorafenib (S) in desmoid tumor, (DT) (ALLIANCE A091105)

DOI

Google Scholar

Gounder, Mrinal M. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J Clin Oncol - 2018

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091105

Phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407

Google Scholar

Govindan, R. , Bogart, J. A. , Wang, X. , Hodgson, L. D. ... - - J. Clin. Oncol. - 2009

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30407

A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non small cell lung cancer: CALGB 30407 early evaluation of feasibility and toxicity

Google Scholar

Govindan, R. , Bogart, J. A. , Wang, X. , Liu, D. , Kratzke, R. A. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - CALGB-30407

Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407

PubMed

PMC

QxMD

DOI

Google Scholar

Govindan, Ramaswamy , Bogart, Jeffrey , Stinchcombe, Thomas ... - - J Clin Oncol - 2011

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30407

A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.

PubMed

DOI

Google Scholar

Govindan, Ramaswamy , Wang, Xiaofei , Baggstrom, Maria Q ... - - J Thorac Oncol - 2009

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30104

Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

Google Scholar

Grant, B. , Leonard, J. P. , Johnson, J. L. , Kostakoglu, L. , Hsi, E. ... - - Blood - 2010

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50701

A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.

PubMed

PMC

QxMD

DOI

Google Scholar

Grant, Barbara W , Jung, Sin-Ho , Johnson, Jeffrey L ... - - Cancer - 2013

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50701

Menstrual Cycle and Surgical Treatment of Breast Cancer: Findings From the NCCTG N9431 Study

PubMed

PMC

QxMD

DOI

Google Scholar

Grant, Clive S. , Ingle, James N. , Suman, Vera J. ... - - J Clin Oncol - 2009

Manuscript - Primary Endpoint - Primary Analysis - Breast - N9431

Dose-dense weekly paclitaxel (P) in extensive stage small cell lung cancer (ES-SCLC): Cancer and Leukemia Group B (CALGB) 39901

Google Scholar

Graziano, S. L. , Socinski, M. A. , Herndon, J. E., 2nd ... - - Proc Am Soc Clin Oncol - 2003

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39901

Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.

PubMed

DOI

Google Scholar

Graziano, Stephen L , Herndon, James E , Socinski, Mark A ... - - J Thorac Oncol - 2008

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39901

Phase II randomized study of dose-dense docetaxel (Doc) and cisplatin (Cis) every two weeks with pegfilgrastim (Pfil) and darbepoetin alfa (Darb) with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (NSCLC)

Google Scholar

Green, M. R. , Miller, A. A. , Wang, X. , Gu, L. ... - - J. Clin. Oncol. - 2007

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30303

Local excision of distal rectal cancer: An update of Cancer and Leukemia Group B 8984

Google Scholar

Greenberg, J. A. , Shibata, D. , Herndon, J. E. 2nd ... - - Am Soc Colon Rectal Surg - 2008

Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - C8984

Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.

PubMed

DOI

Google Scholar

Greenberg, Jacob A , Shibata, David , Herndon, James E ... - - Dis. Colon Rectum - 2008

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - C8984

Treatment of Myelodysplastic Syndrome with Two Schedules and Doses of Oral Topotecan: A Randomized Phase II Trial by the Cancer and Leukemia Group B (CALGB 19803)

PubMed

PMC

QxMD

DOI

Google Scholar

Grinblatt, David L. , Yu, Daohai , Hars, Vera , Vardiman, James W. ... - - Cancer - 2009

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19803

Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C

Google Scholar

Grothey, A. , Lafky, J. M. , Morlan, B. W. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - GI - N054C

Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7

PubMed

PMC

QxMD

DOI

Google Scholar

Grothey, Axel , Nikcevich, Daniel A. , Sloan, Jeff A. ... - - J Clin Oncol - 2011

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N04C7

Determination of Utility Scores for Control of Chemotherapy-Induced Nausea or Vomiting—CALGB 309801

Google Scholar

Grunberg, S. M. , Weeks, J. , Magnan, W. F. , Herndon, J. 2nd ... - - J Support Oncol - 2009

Manuscript - Primary Endpoint - Primary Analysis - Disparities - CALGB-309801

A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Gupta, Pankaj , Mulkey, Flora , Hasserjian, Robert P. ... - - Invest New Drugs - 2013

Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10105

Persistent Fatigue in Hematopoietic Stem Cell Transplantation Survivors

PubMed

PMC

QxMD

DOI

Google Scholar

Hacker, Eileen Danaher , Fink, Anne M. , Peters, Tara , Park, Chang ... - - Cancer Nurs - 2017

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - Pilot

Real-Time Fatigue and Free-Living Physical Activity in Hematopoietic Stem Cell Transplantation Cancer Survivors and Healthy Controls: A Preliminary Examination of the Temporal, Dynamic Relationship

PubMed

PMC

QxMD

DOI

Google Scholar

Hacker, Eileen Danaher , Kim, Inah , Park, Chang ... - - Cancer Nurs - 2017

Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - Pilot

Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer.

Google Scholar

Haddock, M. , Kim, G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0349

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

PubMed

DOI

Google Scholar

Haddock, Michael G , Swaminathan, Revathi , Foster, Nathan R ... - - J. Clin. Oncol. - 2007

Manuscript - Primary Endpoint - Primary Analysis - GI - N9942

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Halfdanarson, Thorvardur R. , Foster, Nathan R. , Kim, George P. ... - - Oncologist - 2019

Manuscript - Primary Endpoint - Primary Analysis - GI - N064B

Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).

Google Scholar

Haluska, Paul , Bernath, Albert M. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Breast - N0733

Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031

Google Scholar

Harpole, D. , Ballman, K. V. , Oberg, A. L. , Whiteley, G. ... - - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4031

CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC)

Google Scholar

Heist, R. C. Suk , Wang, X. , Hodgson, L. D. , Otterson, G. A. ... - - J. Clin. Oncol. - 2012

Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30704

A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

PubMed

PMC

QxMD

DOI

Google Scholar

Heist, Rebecca S. , Wang, Xiaofei , Hodgson, Lydia ... - - J Thorac Oncol - 2014

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30704

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

PubMed

DOI

Google Scholar

Henderson, I Craig , Berry, Donald A , Demetri, George D ... - - J. Clin. Oncol. - 2003

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9344

Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (ppembro) and standard platinum-based chemotherapy (chemo) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) AFT-09 (Alliance)

DOI

Google Scholar

Hensing, Thomas , Wang, Xiaofei , Kozono, David , Dudek, Arkadius ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Respiratory - AFT-09

Patient Education Level As a Predictor of Survival In Lung Cancer Clinical Trials

PubMed

PMC

QxMD

DOI

Google Scholar

Herndon, James E. , Kornblith, Alice B. , Holland, Jimmie C. ... - - J Clin Oncol - 2008

Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-70601

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases

PubMed

PMC

QxMD

DOI

Google Scholar

Himelstein, Andrew L. , Foster, Jared C. , Khatcheressian, James L. ... - - JAMA - 2017

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - CALGB-70604 , CALGB-150804

CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer

Google Scholar

Himelstein, Andrew L. , Qin, Rui , Novotny, Paul J. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - CALGB-70604

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

PubMed

PMC

QxMD

DOI

Google Scholar

Hines, Stephanie L. , Mincey, Betty , Dentchev, Todor ... - - Breast Cancer Res. Treat. - 2009

Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N03CC

Alliance A091104: A Phase II Trial of MK-2206 in patients with progressive, recurrent/metastatic adenoid cystic carcinoma

Google Scholar

Ho, Alan L , Foster, Nathan R. , Meyers, Jeffrey P. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091104

Alliance A091404: a phase II study of enzalutamide (nsc# 766085) for patients with androgen receptor positive salivary cancers

DOI

Google Scholar

Ho, Alan Loh , Foster, Nathan R. , Zoroufy, Alex J. , Worden, Francis ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Primary Endpoint - Primary Analysis - Experimental - A091404

N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy

Google Scholar

Hobday, T. J. , Stella, P. J. , Fitch, T. R. , Jaslowski, A. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0436

A North Central Cancer Treatment Group (NCCTG) Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline and/or a Taxane.

Google Scholar

Hobday, T. , Rowland, K., Jr , Dueck, A. , Northfelt, D. , Lingle, W. ... - ASCO Breast - Breast Cancer Symposium - 2008

Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0537

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

PubMed

PMC

QxMD

DOI

Google Scholar

Holstein, Sarah A. , Jung, Sin-Ho , Richardson, Paul G. ... - - Lancet Haematol - 2017

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Myeloma - CALGB-100104

Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Google Scholar

Holstein, Sarah A. , Owzar, Kouros , Richardson, Paul G. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Myeloma - CALGB-100104

Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial

Google Scholar

Holtan, S. G. , Foster, N. R. , Erlichman, C. E. , Aubry, M. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N004E

Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Holtan, Shernan G. , Steen, Preston D. , Foster, Nathan R. ... - - PLoS ONE - 2012

Manuscript - Primary Endpoint - Primary Analysis - Experimental - N004E

Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147

Google Scholar

Huang, J. , Sargent, D. J. , Mahoney, M. R. , Thibodeau, S. N. ... - ASCO GI - J Cin Oncol 29, No 4_suppl (February - 2011

Abstract - Primary Endpoint - Primary Analysis - GI - N0147 , NCCTG-N0147

Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147

PubMed

PMC

QxMD

DOI

Google Scholar

Huang, Jocelin , Nair, Suresh G. , Mahoney, Michelle R. ... - - Clin Colorectal Cancer - 2014

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-N0147

Phase I evaluation of sorafenib (SOR) & bevacizumab (BEV) in first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group Trial N0745

Google Scholar

Hubbard, J. , Alberts, S. , Loui, W. , Mahoney, M. , Roberts, L. ... - - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - GI - N0745

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Hubbard, Joleen M. , Mahoney, Michelle R. , Loui, William S. ... - - Target Oncol - 2017

Manuscript - Primary Endpoint - Primary Analysis - GI - N0745

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer

Google Scholar

Hughes, K. S. , Schnaper, L. , Cirrincione, C. T. , Berry, D. A. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-9343

Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

PubMed

PMC

QxMD

DOI

Google Scholar

Hughes, Kevin S. , Schnaper, Lauren A. , Bellon, Jennifer R. ... - - J. Clin. Oncol. - 2013

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - CALGB-9343

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.

PubMed

DOI

Google Scholar

Hughes, Kevin S , Schnaper, Lauren A , Berry, Donald ... - - N. Engl. J. Med. - 2004

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9343

Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E.

Google Scholar

Hume, C. Bueno , Moreno-Aspitia, A. , Hillman, D. , Chen, B. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N083E

Local-Regional Recurrence (LRR) Data from the American College of Surgeons Oncology Group (ACOSOG) Z1041 (Alliance): A Randomized Neoadjuvant Trial of Sequential Versus Concurrent Anthracycline with Trastuzumab and Paclitaxel Plus Trastuzumab in HER2-Positive (HER2+) Breast Cancer (BC)

Google Scholar

Hunt, Kelly K. , Suman, Vera J. , Meric-Bernstam, Funda ... - SSO - - 2019

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401

PubMed

PMC

QxMD

DOI

Google Scholar

Hurria, Arti , Cirrincione, Constance T. , Muss, Hyman B. ... - - J Clin Oncol - 2011

Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-99809 , CALGB-360401

Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809

PubMed

PMC

QxMD

Google Scholar

Hurwitz, M. D. , Halabi, S. , Archer, L. , Mcginnis, L. S. ... - - Cancer - 2011

Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-99809

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.

PubMed

DOI

Google Scholar

Hurwitz, Mark D , Halabi, Susan , Ou, San-San , McGinnis, Lamar S ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2008

Manuscript - Primary Endpoint - Preliminary Analysis - GU - CALGB-99809

Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) (Alliance) CALGB 40903

DOI

Google Scholar

Hwang, E. Shelley , Duong, Stephanie , Bedrosian, Isabelle ... - SABCS - Cancer Res - 2017

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40903

Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657

Google Scholar

Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - - Cancer Res. - 2009

Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-150007

MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: Preliminary Findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657

Google Scholar

Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - RSNA - Radiological Society of North America 94th Scientific Assembly and Annual Meeting - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-150007

Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL

PubMed

PMC

QxMD

DOI

Google Scholar

Hylton, Nola M. , Blume, Jeffrey D. , Bernreuter, Wanda K. ... - - Radiology - 2012

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-150007

Reproducibility of Random Periareolar Fine Needle Aspiration in a Multi-Institutional Cancer and Leukemia Group B (CALGB) Cross-Sectional Study

PubMed

PMC

QxMD

DOI

Google Scholar

Ibarra-Drendall, Catherine , Wilke, Lee G. , Zalles, Carola ... - - Cancer Epidemiol. Biomarkers Prev. - 2009

Manuscript - Primary Endpoint - Primary Analysis - Prevention - Comprehensive

Can a Gastric Cancer Risk Survey Identify High-Risk Patients for Endoscopic Screening? A Pilot Study

PubMed

PMC

QxMD

DOI

Google Scholar

In, Haejin , Langdon-Embry, Marisa , Gordon, Lauren ... - - J. Surg. Res. - 2018

Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - Pilot

A Pilot Case Control Study: Could a Gastric Cancer Risk Screening Tool Help Identify High Risk Patients for Endoscopic Screening in the US?

Google Scholar

In, Haejin , Langdon-Embry, Marisa , Gordon, Lauren ... - ASCO GI - J Clin Oncol - 2018

Abstract - Primary Endpoint - Primary Analysis - Disparities - Pilot

A Pilot Case Control Study: Could a Gastric Cancer Risk Screening Tool Help Identify High Risk Patients for Endoscopic Screening in the US?

DOI

Google Scholar

In, Haejin , Langdon-Embry, Marisa , Gordon, Lauren ... - SSO - Ann. Surg. Oncol. - 2018

Abstract - Primary Endpoint - Primary Analysis - Disparities - Pilot

Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.

PubMed

PMC

QxMD

DOI

Google Scholar

Inwards, D J , Fishkin, P A , LaPlant, B R , Drake, M T , Kurtin, P J ... - - Ann. Oncol. - 2014

Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N078D

Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma

Google Scholar

Inwards, D. J. , Fishkin, P. , Laplant, B. R. , Drake, M. T. ... - ASH - ASH Annual Meeting Abstracts - 2012

Abstract - Primary Endpoint - Primary Analysis - Lymphoma - N078D

Long-term Results of the Treatment of Patients With Mantle Cell Lymphoma With Cladribine (2-CDA) Alone (95-80-53) or 2-CDA and Rituximab (N0189) in the North Central Cancer Treatment Group

PubMed

PMC

QxMD

DOI

Google Scholar

Inwards, David J. , Fishkin, Paul A. S. , Hillman, David W. ... - - Cancer - 2008

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Lymphoma - N0189 , NCCTG-95-80-53

NCCTG N0272: phase II trial of imatinib mesylate; (gleevec; sti571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma: a north central cancer treatment group study.

Google Scholar

Jaeckle, K. A. , Anderson, S. K. , Kosel, M. , Sarkaria, J. ... - SNO - Neuro-oncology - 2011

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0272

NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study

Google Scholar

Jaeckle, K. A. , Schiff, D. , Anderson, S. K. , Galanis, E. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0572

Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials

Google Scholar

Jaeckle, K. A. , Wu, W. , Kosel, M. , Flynn, P. J. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N047D

Phase I/II trial of sorafenib and CCI-779 in patients with recurrent glioblastoma (GBM)

Google Scholar

Jaeckle, K. , Anderson, K. , Sarkaria, J. , Decker, P. , Buckner, J. ... - ICTT - - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - NCCTG-N0572

Results of a phase II trial of vorinostat in patients with recurrent glioblastoma: Evidence of post-treatment histone acetylation in tumor tissue and pharmacokinetic analysis: North Central Cancer Treatment Group (NCCTG) study N047B

Google Scholar

Jaeckle, K. , Maurer, M. , Reid, J. , Ames, M. , Giannini, C. ... - TAT - - 2007

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N047B

NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi)

Google Scholar

Jaeckle, K. , Schiff, D. , Anderson, S. , Galanis, E. , Stella, P. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0572

Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma

PubMed

PMC

QxMD

DOI

Google Scholar

Jaeckle, Kurt A. , Ballman, Karla , Furth, Alfred ... - - Neurology - 2009

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0475

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

PubMed

DOI

Google Scholar

Jaeckle, Kurt A , Anderson, S K , Twohy, Erin L , Dixon, Jesse G ... - - J. Neurooncol. - 2019

Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0272

CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III randomized study of RT vs. RT+TMZ vs. TMZ for newly diagnosed 1p/19q-codeleted anaplastic glioma. Analysis of patients treated on the original protocol design

Google Scholar

Jaeckle, Kurt , Vogelbaum, Michael , Ballman, Karla ... - AAN - Neurology - 2016

Abstract - Primary Endpoint - Comprehensive Analysis - Neuro-Onc - N0577

CODEL (Alliance N0577; EORTC 26081/22086 ; NRG 1071; NCIC CEC-2): A Phase III Randomized Intergroup Study for patients (pts) with newly diagnosed 1p/19q codeleted anaplastic glioma. Preliminary analysis of patients treated on the original protocol design with RT vs. RT + concomitant/adjuvant TMZ vs. TMZ alone

Google Scholar

Jaeckle, Kurt , Voglebaum, Michael , Ballman, Karla ... - SNO - Neuro Oncol - 2015

Abstract - Primary Endpoint - Comprehensive Analysis - Neuro-Onc - N0577

Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

PubMed

PMC

QxMD

DOI

Google Scholar

Jahan, Thierry , Gu, Lin , Kratzke, Robert , Dudek, Arkadiusz ... - - Lung Cancer - 2012

Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30107

Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant t